These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 12350250)

  • 1. Procedures for reliable estimation of viral fitness from time-series data.
    Bonhoeffer S; Barbour AD; De Boer RJ
    Proc Biol Sci; 2002 Sep; 269(1503):1887-93. PubMed ID: 12350250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transmitted human immunodeficiency virus type 1 carrying the D67N or K219Q/E mutation evolves rapidly to zidovudine resistance in vitro and shows a high replicative fitness in the presence of zidovudine.
    García-Lerma JG; MacInnes H; Bennett D; Weinstock H; Heneine W
    J Virol; 2004 Jul; 78(14):7545-52. PubMed ID: 15220429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conflicting Selection Pressures Will Constrain Viral Escape from Interfering Particles: Principles for Designing Resistance-Proof Antivirals.
    Rast LI; Rouzine IM; Rozhnova G; Bishop L; Weinberger AD; Weinberger LS
    PLoS Comput Biol; 2016 May; 12(5):e1004799. PubMed ID: 27152856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Practical applications of viral fitness in clinical practice.
    Bates M; Wrin T; Huang W; Petropoulos C; Hellmann N
    Curr Opin Infect Dis; 2003 Feb; 16(1):11-8. PubMed ID: 12821824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Virus fitness: concept, quantification, and application to HIV population dynamics.
    Quiñones-Mateu ME; Arts EJ
    Curr Top Microbiol Immunol; 2006; 299():83-140. PubMed ID: 16568897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modeling and estimation of replication fitness of human immunodeficiency virus type 1 in vitro experiments by using a growth competition assay.
    Wu H; Huang Y; Dykes C; Liu D; Ma J; Perelson AS; Demeter LM
    J Virol; 2006 Mar; 80(5):2380-9. PubMed ID: 16474144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Adherence and resistance].
    Klimkait T; Vernazza P
    Ther Umsch; 2004 Oct; 61(10):631-4. PubMed ID: 15532193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Replication capacity, biological phenotype, and drug resistance of HIV strains isolated from patients failing antiretroviral therapy.
    Nicastri E; Sarmati L; d'Ettorre G; Palmisano L; Parisi SG; Uccella I; Rianda A; Concia E; Vullo V; Vella S; Andreoni M
    J Med Virol; 2003 Jan; 69(1):1-6. PubMed ID: 12436471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Understanding hepatitis C viral dynamics with direct-acting antiviral agents due to the interplay between intracellular replication and cellular infection dynamics.
    Guedj J; Neumann AU
    J Theor Biol; 2010 Dec; 267(3):330-40. PubMed ID: 20831874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decrease of replicative capacity of HIV isolates after genotypic guided change of therapy.
    Sarmati L; Nicastri E; Montano M; Dori L; Buonomini AR; d'Ettorre G; Gatti F; Parisi SG; Vullo V; Andreoni M
    J Med Virol; 2004 Apr; 72(4):511-6. PubMed ID: 14981751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Principal component analysis of general patterns of HIV-1 replicative fitness in different drug environments.
    Martins JZ; Chappey C; Haddad M; Whitcomb JM; Stawiski E; Petropoulos CJ; Bonhoeffer S
    Epidemics; 2010 Jun; 2(2):85-91. PubMed ID: 21352778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutation and control of the human immunodeficiency virus.
    Stengel RF
    Math Biosci; 2008 Jun; 213(2):93-102. PubMed ID: 18439629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can modulation of viral fitness represent a target for anti-HIV-1 strategies?
    Clementi M
    New Microbiol; 2004 Jul; 27(3):207-14. PubMed ID: 15460522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombination in HIV and the evolution of drug resistance: for better or for worse?
    Bretscher MT; Althaus CL; Müller V; Bonhoeffer S
    Bioessays; 2004 Feb; 26(2):180-8. PubMed ID: 14745836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimation of an in vivo fitness landscape experienced by HIV-1 under drug selective pressure useful for prediction of drug resistance evolution during treatment.
    Deforche K; Camacho R; Van Laethem K; Lemey P; Rambaut A; Moreau Y; Vandamme AM
    Bioinformatics; 2008 Jan; 24(1):34-41. PubMed ID: 18024973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resistance and replicative capacity of HIV-1 strains selected in vivo by long-term enfuvirtide treatment.
    Menzo S; Castagna A; Monachetti A; Hasson H; Danise A; Carini E; Bagnarelli P; Lazzarin A; Clementi M
    New Microbiol; 2004 Apr; 27(2 Suppl 1):51-61. PubMed ID: 15646065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Virological fitness of HIV in patients with resistance to enfuvirtide.
    Chibo D; Roth N; Roulet V; Skrabal K; Gooey M; Carolan L; Nicholls J; Papadakis A; Birch C
    AIDS; 2007 Sep; 21(14):1974-7. PubMed ID: 17721108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV-1 reverse transcriptase inhibitor resistance mutations and fitness: a view from the clinic and ex vivo.
    Martinez-Picado J; Martínez MA
    Virus Res; 2008 Jun; 134(1-2):104-23. PubMed ID: 18289713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutation Q95K enhances N155H-mediated integrase inhibitor resistance and improves viral replication capacity.
    Fun A; Van Baelen K; van Lelyveld SF; Schipper PJ; Stuyver LJ; Wensing AM; Nijhuis M
    J Antimicrob Chemother; 2010 Nov; 65(11):2300-4. PubMed ID: 20736234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.